• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

    3/8/23 5:30:00 PM ET
    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Computer Software: Prepackaged Software
    Technology
    Diversified Commercial Services
    Miscellaneous
    Get the next $BBAI alert in real time by email

    Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection with the following special purpose acquisition companies ("SPACs"): BigBear.ai Holdings, Inc. f/k/a GigCapital4 Inc. (NYSE:BBAI), Senti Biosciences, Inc. f/k/a Dynamics Special Purpose Corp (NASDAQGM:SNTI), Tango Therapeutics, Inc. f/k/a BCTG Acquisition Corp (NASDAQGM:TNGX), and Boxed, Inc. f/k/a Seven Oaks Acquisition Corp (NYSE:BOXD).

    If you are an affected investor, and you want to learn more about this investigation, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (972) 521-6868, or via email at [email protected]. There is no cost or fee to you.

    The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 23 years of experience in complex securities litigation and transactional matters.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005867/en/

    Get the next $BBAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBAI
    $BOXD
    $SNTI
    $TNGX

    CompanyDatePrice TargetRatingAnalyst
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    BigBear.ai Inc.
    $BBAI
    1/7/2026$6.00Overweight → Neutral
    Cantor Fitzgerald
    Tango Therapeutics Inc.
    $TNGX
    11/18/2025Peer Perform
    Wolfe Research
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    BigBear.ai Inc.
    $BBAI
    3/7/2025$2.50 → $4.00Outperform → Market Perform
    Northland Capital
    BigBear.ai Inc.
    $BBAI
    12/30/2024$3.00 → $7.00Buy
    H.C. Wainwright
    More analyst ratings

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braden Pamela Joyce sold $320,000 worth of shares (80,000 units at $4.00), decreasing direct ownership by 14% to 508,687 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    3/16/26 5:15:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 10,757 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Lu Timothy K covered exercise/tax liability with 80,666 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:30 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi

    3/19/26 11:00:00 AM ET
    $ATOS
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $

    3/6/26 5:33:52 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

    ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura

    3/5/26 7:01:00 AM ET
    $ERAS
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    SEC Filings

    View All

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mizuho initiated coverage on Tango Therapeutics with a new price target

    Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00

    2/23/26 8:40:01 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigBear.ai downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded BigBear.ai from Overweight to Neutral and set a new price target of $6.00

    1/7/26 8:53:55 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Wolfe Research initiated coverage on Tango Therapeutics

    Wolfe Research initiated coverage of Tango Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BigBear.ai Inc.

    144 - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    3/12/26 10:21:21 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by BigBear.ai Inc.

    144 - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    3/6/26 4:06:44 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 filed by Tango Therapeutics Inc.

    S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)

    3/5/26 7:30:54 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Braden Pamela Joyce bought $209,999 worth of shares (140,939 units at $1.49), increasing direct ownership by 46% to 446,396 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    6/6/24 5:52:55 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Braden Pamela Joyce bought $96,048 worth of shares (50,025 units at $1.92), increasing direct ownership by 20% to 305,457 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    12/21/23 5:21:13 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg

    1/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology